, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Aadi Biosciences, we had the pleasure of speaking with Nam Bui, MD, and Ciara Kelly, MBBCh, BAO, about long-term findings from the phase 2 AMPECT trial (NCT02494570) investigating nab-sirolimus (Fyarro) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa). Dr Bui is a sarcoma specialist and a clinical assistant professor of medicine at the Stanford Cancer Institute in California. Dr Kelly is the interim clinical director of the Sarcoma Oncology Service at Memorial Sloan Kettering Cancer Center in New York, New York.

In our exclusive interview, Drs Bui and Kelly discussed key long-term efficacy and safety findings from AMPECT, how nab-sirolimus performed in patients requiring dose reductions on the trial, and the clinical utility of this agent in all patients with PEComa, regardless of biomarker status.

That’s all we have for today! Thank you for listening to this episode of 

, sponsored by Aadi Biosciences. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Nam Bui, MD

Articles

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa